SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") PGNX stock prior to October 2, 2019.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Progenics to Lantheus Holdings, Inc. ("Lantheus") LNTH. Under the terms of the deal, Progenics shareholders will receive 0.2502 shares of Lantheus stock for each share of Progenics stock. To learn more about the action and your rights, go to:

https://www.zlk.com/mna/progenics-pharmaceuticals-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Progenics merger investigation concerns whether the Board of Progenics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Lantheus is underpaying for Progenics shares, thus unlawfully harming Progenics shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com